Articles from Enovis Corporation

Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSEENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSEENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the “Board”) of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO.  As part of the Company’s succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to serve as the Company’s next CEO.

Wilmington, DE, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2024 financial results on Wednesday, February 26th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call as well as a webcast can be accessed from the "Investors" section of Enovis' website at www.enovis.com.

Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025.

Wilmington, DE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 43nd Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 13th, 2025, at 9:45 a.m. PST (12:45 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website (www.enovis.com) at Events and Presentations.      

Wilmington, DE, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Wilmington, DE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com.

WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSEENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company’s U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis’ Reconstructive (Recon) Business Group.

With the upcoming launch of the innovative Tarsoplasty solution and live demonstrations of the Better Step patient-focused platform, Enovis™ Foot & Ankle continues to drive its portfolio into “The Fast Lane.”

First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller.

Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert

Wilmington, DE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET.

Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming earnings results conference call. The call will still take place on August 7, 2024, but will now be held at 8:00 a.m. Eastern Time, instead of the previously announced time. There is no change to the date, the dial-in or webcasting information. A presentation related to the call will be available on ir.enovis.com.

Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com.

New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity and efficiency. First surgery using AltiVate Reverse® Glenoid System conducted by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024.

Wilmington, DE, May 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Wilmington, DE, May 02, 2024 (GLOBE NEWSWIRE) --   Enovis™ Corporation (NYSEENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended March 29, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET.

Wilmington, DE, April 17, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2024 financial results on Thursday, May 2, 2024 at 8:00 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the “Investors” section.

Wilmington, DE, March 28, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV) ("Enovis" or the "Company"), an innovation-driven, medical technology growth company, today announced that management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. The presentation is scheduled to begin at 3:45 p.m. Eastern Time on Tuesday, April 9, 2024.

Wilmington, DE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSEENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

WILMINGTON, DE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology company, will showcase its latest technologies across the orthopedic care continuum at the American Academy of Orthopedic Surgeons Annual Meeting 2024. In addition, the Company will present itself as a newly integrated company following the acquisition of orthopedic leader LimaCorporate S.p.A (“Lima”).

Wilmington, DE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that Brady Shirley, President and COO, Ben Berry, CFO, and Louis Vogt, Group President Recon will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 5:30pm p.m. ET (2:30 p.m. PT) on Monday, February 12, 2024.

New solutions in Percutaneous and Open Bunion procedures, External Fixation, and STAR® Ankle will be featured as part of the company’s growing evidence-based, innovative portfolio.

Wilmington, DE, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2023 financial results on Thursday, February 22, 2024 at 8:30AM ET and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the “Investors” section.

The newest innovation in unloader braces is comfortable, easy to use and effective.

WILMINGTON, Del., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology growth company, today announced that it closed the acquisition of LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions. 

Wilmington, DE, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 42nd Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 8th, 2024, at 9:45 a.m. PST (12:45 p.m. EST). A link to the live audio webcast, as well as a replay of this event, will be available on the company’s website at Events and Presentations.      

Wilmington, DE, Dec. 05, 2023 (GLOBE NEWSWIRE) --  Enovis Corporation (NYSEENOV), an innovation-driven medical technology growth company, today announced that Brady R. Shirley, the Company’s President and COO, has informed the Company’s Board of Directors of his plans to retire at the end of Q1 2025.  Brady will step down from his current position as President and COO on April 1, 2024, and assume the role of Executive Advisor, continuing to focus on the successful integration of the pending Lima acquisition, innovation, and mentorship of Enovis business leaders. Mr. Shirley’s transition to retirement at the end of the first quarter 2025 will be thoughtfully managed with ample time for overlap with other relevant executives within the organization. He will remain a member of the Company’s Board of Directors.

Wilmington, DE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced that it will participate in the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, 2023.

Company unveils new ARVIS® augmented reality system, the EMPOWR™ blade stem and more at upcoming conference in Texas

Wilmington, DE, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) today announced the pricing of $400 million aggregate principal amount of 3.875% Convertible Senior Notes due 2028 (the “Notes”) in a private offering (the “Offering”). In connection with the Offering, Enovis has granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $60 million aggregate principal amount of the Notes on the same terms and conditions. The sale of the Notes to the initial purchasers is expected to settle on October 24, 2023, subject to customary closing conditions.

Wilmington, DE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) today released the following preliminary information about its performance for the third quarter ended September 29, 2023.

Wilmington, DE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) today announced its intention to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due 2028 (the “Notes”) in a private offering (the “Offering”). In connection with the Offering, Enovis expects to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $60 million aggregate principal amount of the Notes on the same terms and conditions.

Wilmington, DE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its third quarter 2023 financial results on Tuesday, November 7, 2023 at 8:00 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section.

New solutions in Percutaneous and Open Bunion procedures, External Fixation, and Patient Specific Instrumentation, will be featured as part of the company’s growing evidence based, high tech portfolio.

Wilmington, DE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:

Wilmington, DE, July 11, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its second quarter 2023 financial results on Thursday August 3, 2023 at 8:30 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section.

Wilmington, DE, July 06, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced today that it has been recognized as one of America’s Greatest Workplaces 2023 by Newsweek. Newsweek partnered with Plant-A Insights Group, a market-data research firm, to identify America’s Greatest Workplaces by conducting a large-scale employer study based on over 389,000 company reviews in the United States.

Wilmington, DE, June 28, 2023 (GLOBE NEWSWIRE) --  Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that it closed the acquisition of Novastep®, a subsidiary of Amplitude Surgical SA (Paris: AMPLI), and global developer of clinically proven foot and ankle solutions.

Wilmington, DE, April 13, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2023 financial results on Thursday, May 4, 2023 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the “Investors” section.

Strengthens Foot and Ankle Portfolio with Leading Minimally Invasive Surgery (MIS) Platform, including MIS Bunion System and Furthers Global Expansion Strategy

CEO Matt Trerotola to be named Chair and Director Sharon Wienbar to become Lead Independent Director following retirement of current Chair Mitchell P. Rales at 2023 Annual Meeting

Medtech Leader Highlights Power of Collaboration in Its Continued Success and Innovation

Wilmington, DE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSEENOV), an innovation-driven medical technology company, announced that it has been recognized as one of America’s Greatest Workplaces for Diversity by Newsweek. The listing recognizes the best workplaces in the U.S. for their commitment to diversity, equity and inclusion (DEI) in the many categories of diversity.

With innovative offerings spanning across foot and ankle indications, Enovis will highlight its latest products including knotless suture anchors, bone fixation systems and disruptive NiTiNOL technologies.

Innovative new staples combine strength with unmatched, sustained dynamic compression for mid-foot and first MTP joint fusions

Wilmington, DE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSEENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 41st Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 9th, 2023, at 3:00 p.m. PST (6:00 p.m. EST). A link to the live audio webcast, as well as a replay of this event, will be available on the company’s website at Events and Presentations.      

The approval of the STAR PSI System marks an impactful milestone by allowing surgeons to provide a personalized pre-operative plan for their total ankle replacement patients

Designed with our patented and proven NiTiNOL technology, DynaNail Helix™ revolutionizes dynamic compression in foot & ankle fusion

Wilmington, DE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSEENOV), an innovation-driven medical technology company, announced that the company’s ARVIS® Augmented Reality Surgical Guidance System received the Industry Innovation Award at the this year’s American Academy of Hip and Knee Surgeons (AAHKS) Annual Meeting. This annual award recognizes cutting-edge innovation in products, procedures and services in the field of Hip and Knee Arthroplasty.

DJO® is now part of the Enovis™ family.* Enovis Corporation, an innovation-driven medical technology growth company, announced today the launch of the Arsenal Ankle Plating System™. This system consists of 37 anatomically designed plates throughout nine plate families, offering a plating solution for any ankle fracture.